Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELAB NASDAQ:ENVB NASDAQ:GLMD NASDAQ:TRVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELABPMGC$4.84+3.9%$7.23$4.57▼$1,837.50$2.41M0.178.12 million shs129,819 shsENVBEnveric Biosciences$1.05-3.7%$1.23$1.01▼$8.40$3.67M0.58298,333 shs160,960 shsGLMDGalmed Pharmaceuticals$1.29+1.6%$1.68$1.15▼$23.80$2.10M0.56228,954 shs126,482 shsTRVNTrevena$0.25+20,733.3%$0.63$0.00▼$7.85$240K0.452,165 shs8,805 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELABPMGC+3.86%-30.51%-31.54%-35.68%-99.69%ENVBEnveric Biosciences-3.67%-27.59%-8.70%-16.67%-86.28%GLMDGalmed Pharmaceuticals+1.57%-7.19%-20.86%-13.42%-58.79%TRVNTrevena0.00%-9.09%0.00%-76.24%-93.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELABPMGC0.7385 of 5 stars0.04.00.00.02.30.00.6ENVBEnveric Biosciences3.0062 of 5 stars3.54.00.00.04.00.00.6GLMDGalmed Pharmaceuticals1.0527 of 5 stars0.03.00.00.01.92.50.6TRVNTrevena1.6084 of 5 stars3.04.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELABPMGC 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00852.38% UpsideGLMDGalmed Pharmaceuticals 2.00HoldN/AN/ATRVNTrevena 2.00Hold$5.001,900.00% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELABPMGC$1.71M4.19N/AN/A$6.09 per share0.79ENVBEnveric BiosciencesN/AN/AN/AN/A$0.67 per shareN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/A$9.87 per shareN/ATRVNTrevena$443K0.54N/AN/A($11.07) per share-0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELABPMGC-$6.25M-$433.87N/A∞N/AN/A-62.73%-52.83%N/AENVBEnveric Biosciences-$9.57M-$38.38N/AN/AN/AN/A-341.48%-240.71%11/12/2025 (Estimated)GLMDGalmed Pharmaceuticals-$7.52M-$16.66N/A∞N/AN/A-20.69%-18.41%11/12/2025 (Estimated)TRVNTrevena-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%11/5/2025 (Estimated)Latest TRVN, GLMD, ENVB, and ELAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ENVBEnveric Biosciences-$5.25-$0.97+$4.28-$0.97N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELABPMGCN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/ATRVNTrevenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELABPMGCN/A22.4022.40ENVBEnveric BiosciencesN/A2.422.42GLMDGalmed PharmaceuticalsN/A8.719.02TRVNTrevenaN/A2.422.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELABPMGC22.22%ENVBEnveric Biosciences13.82%GLMDGalmed Pharmaceuticals76.14%TRVNTrevena13.56%Insider OwnershipCompanyInsider OwnershipELABPMGC0.24%ENVBEnveric Biosciences3.20%GLMDGalmed Pharmaceuticals19.80%TRVNTrevena2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELABPMGC181.48 million1.48 millionN/AENVBEnveric Biosciences203.25 million3.14 millionNot OptionableGLMDGalmed Pharmaceuticals201.65 million1.33 millionNot OptionableTRVNTrevena40959,000841,000OptionableTRVN, GLMD, ENVB, and ELAB HeadlinesRecent News About These CompaniesSoftball: Conrad Weiser’s Alex Trevena earns statewide player of the year award; 5 other Berks players honoredJuly 8, 2025 | msn.comTrevena, Inc. (TRVN) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comTrevena Enters Securities Exchange Agreement with InvestorMay 15, 2025 | tipranks.comBerks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball winApril 11, 2025 | readingeagle.comRVanessa Hudgens and Oliver Trevena Appear at Expo West for CaliwaterMarch 9, 2025 | msn.comJMP Securities downgrades Trevena (TRVN) to a HoldDecember 27, 2024 | markets.businessinsider.com‘Plane’ Actor Oliver Trevena Signs With Untitled EntertainmentDecember 16, 2024 | yahoo.comLyme Regis town councillor John Trevena stand downDecember 11, 2024 | bridportnews.co.ukBTrevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock NowDecember 10, 2024 | zacks.comTrevena appoints new financial chiefNovember 29, 2024 | investing.comTrevena Appoints Katrine Sutton as New CFONovember 27, 2024 | tipranks.comHC Wainwright & Co. Downgrades Trevena (TRVN)November 16, 2024 | msn.comTrevena, Inc. Navigates Financial Challenges and Strategic ChangesNovember 9, 2024 | msn.comChester County biopharm firm's latest layoffs impact its C-suiteNovember 7, 2024 | bizjournals.comTrevena teeters in dangerous territory, terminating CEO and other execs amid strategic reviewNovember 7, 2024 | fiercebiotech.comFTrevena Reports Third Quarter 2024 Results and Provides Business UpdateNovember 7, 2024 | globenewswire.comWhy Trevena (TRVN) Stock Is Down 43% TodayOctober 8, 2024 | msn.comTrevena, Inc. Faces Delisting from NasdaqOctober 6, 2024 | msn.comTrevena Announces Receipt of Nasdaq Delisting NotificationOctober 4, 2024 | globenewswire.comLearn to Evaluate (TRVN) using the ChartsSeptember 16, 2024 | news.stocktradersdaily.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRVN, GLMD, ENVB, and ELAB Company DescriptionsPMGC NASDAQ:ELAB$4.84 +0.18 (+3.86%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$4.74 -0.11 (-2.17%) As of 09/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.Enveric Biosciences NASDAQ:ENVB$1.05 -0.04 (-3.67%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$1.06 +0.01 (+0.95%) As of 09/3/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Galmed Pharmaceuticals NASDAQ:GLMD$1.29 +0.02 (+1.57%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$1.28 -0.01 (-0.39%) As of 09/3/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Trevena NASDAQ:TRVN$0.25 +0.25 (+20,733.33%) As of 09/2/2025 11:36 AM EasternTrevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
